For example, the range of reported TFF1-positive cases ranged from 16% to 90% in gastric cancer [13,15,16,17], from 51% to 98% in cholangiocarcinoma [18,19,20], from 0% to 100% in breast cancer [14,21,22,23], from 0% to 100% in colorectal cancer [24,25,26,27], from 0% to 40% in pulmonary adenocarcinoma [28,29,30,31], from 0% to 14% in serous ovarian carcinoma [28,32,33], from 0% to 25% in clear cell renal cell carcinoma [28,32,34], from 0% to 91% in prostate cancer [28,35,36], and from 55% to 95% in pancreatic cancer [10,37,38]. Here, TFF1 is linked to pancreatic neoplasm.